by admin | Mar 16, 2023 | Press Releases
Anaveon, a clinical stage, immuno-oncology company, today announced the first patient dosed with ANV419 in the OMNIA-2 (ANV419-102) study – a Phase I/II study assessing the safety, tolerability and preliminary efficacy of ANV419 for the treatment of patients with relapsed / refractory multiple myeloma as monotherapy and in combination with daratumumab and hyaluronidase-fihj1, or with lenalidomide plus dexamethasone. ANV419 is a powerful, IL-2Rb selective IL-2 agonist, which has been specifically designed to enable the delivery of high dose IL-2. 
by admin | Nov 30, 2022 | Press Releases
Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dr Eduard Gasal as Chief Medical Officer (CMO). 
by admin | Nov 10, 2022 | Press Releases
Anaveon, a clinical stage, immuno-oncology company, today announced updated clinical data from the ongoing Phase I study of ANV419 in patients with solid tumors at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA 
by admin | Oct 31, 2022 | Press Releases
Anaveon, a clinical stage, immuno-oncology company, today announced that it will present two posters on its lead program ANV419 at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA. 
by admin | Sep 10, 2022 | Press Releases
Anaveon, a clinical-stage immuno-oncology company, today announces updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective interleukin-2 (IL-2) agonist, in poster presentations at the European Society for Medical Oncology (ESMO) Congress 2022, taking place in Paris, September 9 – 13, 2022. 
Anaveon presents clinical trial OMNIA-2 at the American Society of Clinical Oncology 2023 Annual MeetingJune 5, 2023
Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual MeetingJune 3, 2023
Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual MeetingApril 18, 2023